A phase I/II trial of bevacizumab (Avastin), erlotinib (Tarceva), and imatinib (Gleevec) in the treatment of patients with advanced renal cell carcinoma.

Trial Profile

A phase I/II trial of bevacizumab (Avastin), erlotinib (Tarceva), and imatinib (Gleevec) in the treatment of patients with advanced renal cell carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Imatinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2011 Planned end date changed from 1 Dec 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 01 Nov 2010 Planned end date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top